Skip to main content Accessibility help

Venous thromboembolism in psychogeriatric in-patients – A study of risk assessment, incidence, and current prophylaxis prescribing

  • Xinsheng Liu (a1), Fintan O'Rourke (a1) (a2) and Huong Van Nguyen (a1) (a2)


Background: While venous thromboembolism (VTE) risk assessment and prophylaxis is well established for medical and surgical in-patients, there is a paucity of evidence, and therefore guidelines, in this area for psychogeriatric in-patients. We wished to determine VTE incidence, risk, and use of prophylaxis, in a psychogeriatric in-patient population.

Methods: Retrospective audit of consecutive psychogeriatric patients aged 65 years and over admitted to Bankstown Hospital over a 3-year period, 2007–2009. Using an adapted VTE risk scoring system, patients were assigned as low, medium, or high VTE risk.

Results: A total of 192 patients were included in the study. Mean age was 79.1 ± 7.0 years. Out of the total, 55.2% of patients had diagnosis of dementia, and 33.3% had depression. Overall, 81.8% (157/192) were assessed as low risk, and 18.2% (35/192) as medium risk. Also, 16.7% (32/192) received VTE prophylaxis.

Four new VTE events occurred in medium-risk group, and one in low-risk group (p = 0.004). Overall VTE incidence was 10.5/10,000 patient-days, but 44.2 per 10,000 in medium-risk group. VTE risk score was predictive of VTE events – IRR 6.02 (95% Confidence Intervals (CI) = 1.76–20.7, p = 0.004) for every one-point increment in risk. Depression was associated with significantly higher VTE occurrence (6.3% in those with diagnosis vs. 0.8% without, p = 0.043).

Conclusion: Using a VTE risk scoring system adapted for psychogeriatric in-patients, those assessed to be at medium risk had a significantly increased rate of VTE. On this basis, we would recommend VTE prophylaxis be prescribed for psychogeriatric in-patients assessed to be at medium and high level of risk.


Corresponding author

Correspondence should be addressed to: Dr Fintan O'Rourke, Department of Aged Care and Rehabilitation, Bankstown-Lidcombe Hospital, Eldridge Road, Bankstown, NSW 2200, Australia. Phone: +612 9722 8000; Fax: +612 9722 8275. Email: Fintan.O'


Hide All
Access Economics (2008). The Burden of Venous Thromboembolism in Australia. Report for the Australia and New Zealand Working Party on the Management and Prevention of Venous Thromboembolism. Barton ACT: Access Economics
Agnelli, G. (2004). Prevention of venous thromboembolism in surgical patients. Circulation, 110, IV4IV12.
Alhenc-Gelas, M., Aiach, M. and de Moerloose, P. (2001). Venous thromboembolic disease: risk factors and laboratory investigation. Seminars in Vascular Medicine, 1, 8187.
Australia and New Zealand Working Party on Management and Prevention of VTE (2005). Prevention of Venous Thromboembolism: Best Practice Guidelines for Australia and New Zealand, 3rd edn.Baulkam Hills, New South Wales: Health Education and Management Innovations.
Hägg, S., Jönsson, A. K. and Spigset, O. (2009). Risk of venous thromboembolism due to antipsychotic drug therapy. Expert Opinion on Drug Safety, 8, 537547.
Hägg, S., Spigset, O. and Soderstrom, T. G. (2000). Association of venous thromboembolism and clozapine. Lancet, 355, 11551156.
Liperoti, R., Pedone, C., Lapane, K. L., Mor, V., Bernabei, R. and Gambassi, G. (2005). Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Archives of Internal Medicine, 165, 26772682.
Malý, R., Masopust, J. and Hosak, L. (2008). Assessment of risk of venous thromboembolism and its possible prevention in psychiatric patients. Psychiatry and Clinical Neurosciences, 62, 38
Oger, E. (2000). Incidence of venous thromboembolism: a community-based study in western France. EPI-GETBO Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thrombosis and Haemostasis, 83, 657660.
Parker, C., Coupland, C. and Hippisley-Cox, J. (2010). Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. BMJ, 341, c4245
Parkin, L., Skegg, D. C., Herbison, G. P. and Paul, C. (2003). Psychotic drugs and fatal pulmonary embolism. Pharmacoepidemiology and Drug Safety, 12, 647652.
Radcliffe, J. and Smith, R. (2007). Acute in-patient psychiatry: how patients spend their time on acute psychiatric wards. Psychiatric Bulletin, 31, 167170.
Ray, J. G., Mamdani, M. M. and Yeo, E. L. (2002). Antipsychotic and antidepressant drug use in the elderly and the risk of venous thromboembolism. Thrombosis and Haemostasis, 88, 205209.
Rosendaal, F. R. (1999). Risk factors for venous thrombotic disease. Thrombosis and Haemostasis, 82, 610619.
Strudsholm, U., Johannessen, L., Foldager, L. and Munk-Jorgensen, P. (2005). Increased risk for pulmonary embolism in patients with bipolar disorder. Bipolar Disorders, 7, 7781.
Thomassen, R., Vandenbroucke, J. P. and Rosendaal, F. R. (2001). Antipsychotic medication and venous thrombosis. British Journal of Psychiatry, 179, 6366.
Vandenbroucke, J. al. (1998). Factor V Leiden and fatal pulmonary embolism. Thrombosis and Haemostasis, 79, 511516.
Waage, I. M. and Gedde-Dahl, A. (2003). Pulmonary embolism possibly associated with olanzapine treatment. BMJ, 37, 1384.
Zornberg, G. and Jick, H. (2000). Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet, 356, 12191223.


Venous thromboembolism in psychogeriatric in-patients – A study of risk assessment, incidence, and current prophylaxis prescribing

  • Xinsheng Liu (a1), Fintan O'Rourke (a1) (a2) and Huong Van Nguyen (a1) (a2)


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed